How effective are several generations of everolimus targeted drugs on breast cancer patients?

Everolimus, as an oral inhibitor of the mammalian target of rapamycin (mTOR), belongs to a new generation of targeted drugs. It plays an important role in the treatment of various cancers by inhibiting the mTOR signaling pathway and interfering with the growth, differentiation and metabolism of tumor cells. Especially in the field of breast cancer, the application of everolimus provides a new treatment option for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer.

The indications of everolimus in the treatment of breast cancer are mainly for patients who are resistant to first-line endocrine therapy such as the aromatase inhibitors letrozole or anastrozole. Clinical studies have shown that combined treatment of everolimus and the estrogen inhibitor exemestane can significantly extend the progression-free survival (PFS) of patients and reduce the risk of disease progression. In a clinical study involving 724 patients with breast cancer, patients treated with everolimus plus exemestane experienced a 4.6-month improvement in median time to disease progression or death.

The breast cancer indication effect of everolimus is not only reflected in prolonging survival, but also in improving patients' quality of life. By inhibiting the growth and metastasis of tumor cells, everolimus can relieve patients' discomfort caused by tumor progression, such as pain, dyspnea and other symptoms, thereby improving patients' quality of life.

However, the use of everolimus is not without risks. As a targeted drug, it can cause a range of side effects, including stomatitis, infection, weakness, fatigue, cough and diarrhea. Some patients may also experience serious adverse reactions, such as non-infectious pneumonia, hyperglycemia, hypertension, etc. Therefore, when using everolimus, you must strictly follow the doctor's instructions, monitor various indicators regularly, and deal with adverse reactions in a timely manner.

In short, everolimus, as a new generation of targeted drugs, has demonstrated good efficacy and safety in the treatment of breast cancer. However, its use must be done with caution and under the guidance of a professional physician to ensure maximum benefit for the patient.